Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment
November 05, 2024 08:00 ET
|
Insignis Therapeutics, Inc.
Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
October 07, 2024 08:00 ET
|
Insignis Therapeutics, Inc.
Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.
Insignis Therapeutics Receives FDA Fast Track Designation for IN-001 for Anaphylaxis Treatment
August 13, 2024 07:30 ET
|
Insignis Therapeutics, Inc.
Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.
Safer Skies Ahead: Congress Approves Legislation Requiring Updates to Airline Emergency Medical Kits
May 15, 2024 14:59 ET
|
Asthma and Allergy Foundation of America
Washington, DC, May 15, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating Congressional action that could lead to safer skies for travelers with potentially...
Maryland Becomes Fourth State to Enact Elijah’s Law to Protect Kids with Food Allergies
April 26, 2024 12:06 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., April 26, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) celebrates the signing of Elijah’s Law in Maryland. The legislation, passed by the Maryland...
Global Skin Allergy Testing Market Report 2024-2028 with Analysis of Companies' Market Shares, Proprietary Technologies, Alliances and Patents
April 24, 2024 06:14 ET
|
Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Global Skin Allergy Testing Market" report has been added to ResearchAndMarkets.com's offering.The global market for skin allergy testing is expected...
Auto-Injectors Market revenue to surpass USD 33 Billion by 2036, says Research Nester
February 21, 2024 07:00 ET
|
Research Nester
New York , Feb. 21, 2024 (GLOBE NEWSWIRE) -- The global auto-injectors market size is predicted to expand at 17% CAGR between 2024 and 2036. The market is projected to garner a revenue of USD 33...
AAFA Statement on Uber Eats Super Bowl Ad
February 08, 2024 15:20 ET
|
Asthma and Allergy Foundation of America
Washington, DC, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) issued the following statement which may be attributed to Kenneth Mendez, president and CEO: ...
AAFA Joins Advocates on Capitol Hill in Support of Dillon’s Law and Expanded Access to Epinephrine
October 26, 2023 07:00 ET
|
Asthma and Allergy Foundation of America
Washington, DC, Oct. 26, 2023 (GLOBE NEWSWIRE) -- This week, the Asthma and Allergy Foundation of America (AAFA) is proud to join the unwavering advocacy efforts of Angel and George Mueller, parents...
Epinephrine Market revenue to cross USD 4 Billion by 2033, says Research Nester
July 06, 2023 05:30 ET
|
Research Nester
New York, July 06, 2023 (GLOBE NEWSWIRE) -- The global epinephrine market is estimated to grow at a CAGR of ~12% from 2023 to 2033. The market is estimated to garner a revenue of ~USD 4 billion by...